+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2025-2030- Product Image
Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2025-2030- Product Image
Sale

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6124752
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hepatitis C antiviral market is accelerating through pivotal innovation, evolving clinical strategies, and dynamic policy developments, positioning itself as a focal point for biopharmaceutical investment and healthcare transformation.

Market Snapshot: Hepatitis C Antiviral Market

The Hepatitis C antiviral market has experienced remarkable transformation over the past decade, characterized by the emergence of highly effective direct-acting antivirals and a shift towards precision medicine. With this shift, treatment protocols are now more streamlined, ensuring improved patient outcomes and operational efficiencies across healthcare systems. Key drivers include rapid adoption of targeted therapies, evolving regulatory pathways, and increasing global efforts to reduce disease burden. Industry leaders and regional healthcare networks are leveraging advanced therapeutics to elevate cure rates and optimize resource utilization, setting the market on a trajectory for robust, sustained growth.

Scope & Segmentation

This report delivers an in-depth analysis of the Hepatitis C antiviral market, covering critical segments, regions, and enabling technologies to support strategic planning and market positioning:

  • Product Types: Direct-acting antivirals, interferons, and ribavirin formulations designed for variable patient profiles and treatment aims.
  • Mechanisms of Action: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors—including both non-nucleoside and nucleoside analog approaches.
  • Therapy Types: Combination therapies aimed at maximizing efficacy, and monotherapy protocols for specific patient groups.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail outlets serve acute care, mail-order, and outpatient settings respectively.
  • End Users: Hospitals, outpatient clinics, and homecare providers address diverse care models and patient monitoring needs.
  • Formulations: Injectable and oral dosage forms support adherence strategies and administration flexibility.
  • Genotypes: Genotype 1 to 6 coverage ensures tailored regimens for varied global patient populations.
  • Geographic Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including more than 15 key markets), and Asia-Pacific (including China, India, Japan, Australia, and nine additional countries).
  • Leading Companies: Gilead Sciences, AbbVie, Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, Teva Pharmaceutical, Viatris, Cipla, Natco Pharma, and Hetero Drugs are featured for their strategic developments and market leadership.

Key Takeaways for Senior Stakeholders

  • Direct-acting antivirals now dominate Hepatitis C treatment paradigms, replacing legacy interferon regimens and prompting shorter therapy durations with improved safety profiles for diverse patients.
  • Collaborative regulatory frameworks, including fast-track approvals and priority reviews, have accelerated market access and fueled sustained investment in research and pipeline development.
  • Segmented patient management, informed by genotype stratification and real-world clinical data, is driving more precise and efficient treatment decisions at scale.
  • Regional market variations require manufacturers and providers to tailor supply, pricing models, and distribution methods to local healthcare infrastructures and regulatory environments.
  • Strategic partnerships across pharmaceutical leaders and regional manufacturers are enabling market resilience, especially in supply chain optimization and localized production of antiviral agents.

Tariff Impact: Navigating U.S. Policy Shifts

Recent U.S. tariff policies introduced in 2025 have affected Hepatitis C drug pricing, with import duties on active pharmaceutical ingredients and finished drugs increasing cost pressures across the value chain. Manufacturers are responding by revisiting sourcing strategies, negotiating with suppliers, and implementing regional production solutions. The introduction of differentiated pricing and collaborative risk-sharing agreements further reflects industry adaptability, ensuring continued access and controlled costs. Enhanced digital tracking and consolidated logistics have improved transit efficiency, mitigating financial impact from customs issues and underscoring the industry's supply chain resilience.

Methodology & Data Sources

This report's analysis draws on multi-stage research, beginning with comprehensive secondary reviews of scientific literature, regulatory submissions, and public healthcare data. Primary research included interviews with clinical, regulatory, and supply chain experts, ensuring practical insights into market trends and challenges. Quantitative modeling, triangulation methods, and scenario analysis enhanced robustness, while cross-functional workshops validated findings for real-world application.

Why This Report Matters to Decision-Makers

  • Supports evidence-driven portfolio alignment, helping executives prioritize investments in pan-genotypic drugs and strategic alliances to maximize competitive edge.
  • Delivers pragmatic guidance on optimizing market access, with a clear roadmap for engagement with payers, regulators, and regional partners in shifting market environments.
  • Equips leaders to anticipate policy and technological changes, utilizing actionable segmentation insights and real-world data to guide proactive adaptation.

Conclusion

As Hepatitis C treatment continues to evolve, this report delivers a decision-ready analysis tailored for senior leaders aiming to drive innovation, strengthen partnerships, and expand market reach. Informed strategic action will be key to success in this complex and rapidly progressing sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of pan-genotypic direct-acting antiviral regimens achieving sustained virologic response across diverse patient populations
5.2. Regulatory approval of novel NS5A inhibitor combinations addressing resistant hepatitis C viral strains
5.3. Implementation of simplified treatment protocols and reduced duration DAA regimens in low-resource settings
5.4. Expansion of hepatitis C screening and linkage-to-care programs to identify undiagnosed infections globally
5.5. Development of next-generation NS5B polymerase inhibitors with enhanced resistance barrier and safety profile
5.6. Growing emphasis on real-world evidence demonstrating pangenotypic treatment effectiveness in cirrhotic patient cohorts
5.7. Integration of point-of-care HCV viral load testing to expedite treatment initiation in primary care settings
5.8. Increasing public-private partnerships to support hepatitis C elimination targets through improved access to DAAs
5.9. Focus on direct-acting antiviral pricing strategies and negotiation models in emerging and developing markets
5.10. Adoption of digital health platforms for patient adherence monitoring and outcome tracking in HCV therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antiviral Drugs for the Treatment of Hepatitis C Market, by Product Type
8.1. Introduction
8.2. Direct-Acting Antivirals
8.3. Interferons
8.4. Ribavirin
9. Antiviral Drugs for the Treatment of Hepatitis C Market, by Mechanism of Action
9.1. Introduction
9.2. NS3/4A Protease Inhibitors
9.3. NS5A Inhibitors
9.4. NS5B Polymerase Inhibitors
9.4.1. Non-Nucleoside Inhibitors
9.4.2. Nucleoside Inhibitors
10. Antiviral Drugs for the Treatment of Hepatitis C Market, by Therapy Type
10.1. Introduction
10.2. Combination Therapy
10.3. Monotherapy
11. Antiviral Drugs for the Treatment of Hepatitis C Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Antiviral Drugs for the Treatment of Hepatitis C Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Antiviral Drugs for the Treatment of Hepatitis C Market, by Formulation
13.1. Introduction
13.2. Injectable
13.3. Oral
14. Antiviral Drugs for the Treatment of Hepatitis C Market, by Genotype
14.1. Introduction
14.2. Genotype 1
14.3. Genotype 2
14.4. Genotype 3
14.5. Genotype 4
14.6. Genotype 5
14.7. Genotype 6
15. Americas Antiviral Drugs for the Treatment of Hepatitis C Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Antiviral Drugs for the Treatment of Hepatitis C Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Gilead Sciences, Inc.
18.3.2. AbbVie Inc.
18.3.3. Merck & Co., Inc.
18.3.4. Bristol-Myers Squibb Company
18.3.5. F. Hoffmann-La Roche Ltd
18.3.6. Teva Pharmaceutical Industries Ltd.
18.3.7. Viatris Inc.
18.3.8. Cipla Limited
18.3.9. Natco Pharma Limited
18.3.10. Hetero Drugs Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET: RESEARCHAI
FIGURE 30. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET: RESEARCHSTATISTICS
FIGURE 31. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET: RESEARCHCONTACTS
FIGURE 32. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 116. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 117. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 222. GERMANY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 236. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 237. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 238. FRANCE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 255. ITALY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 256. ITALY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 257. ITALY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 258. ITALY ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antiviral Drugs for the Treatment of Hepatitis C market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • Natco Pharma Limited
  • Hetero Drugs Limited

Related Topics

Related Reports

Hepatitis Therapeutics Market - Global Forecast 2025-2030 - Product Image

Hepatitis Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Direct Acting Antivirals Market - Global Forecast 2025-2030 - Product Image

Direct Acting Antivirals Market - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Hepatitis C Market Report 2025 - Product Image

Hepatitis C Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hepatitis Drugs Market Report 2025 - Product Image

Hepatitis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.